Navigation Links
Kansas City Region Launches Contract Research Initiative To Speed The Development Of Health Care Innovation Worldwide
Date:6/7/2012

OLATHE, Kan., June 6, 2012 /PRNewswire/ --  The Kansas Bioscience Authority announced today the creation of BioResearch Central – a newly formed collaboration involving more than 90 contract research organizations and related service providers dedicated to accelerating the development of new medicines and medical devices to improve the health and well-being of patients worldwide.

(Logo:  http://photos.prnewswire.com/prnh/20120606/CG20424LOGO)

BioResearch Central represents a concerted effort by the contract research community in Greater Kansas City to come together to help the pharmaceutical and medical device industries accelerate their pipelines and improve their process for the development of treatments and therapies that will positively impact global health. The initiative is launching at an important time, as companies increase outsourcing activity to speed the development of new medicines and devices for chronic and emerging diseases while lowering health care costs.

"The formation of BioResearch Central helps to reinforce drug and device developers' recognition that our region is able to meet their outsourcing needs," said Tom Krol, director of commercialization for the KBA. "We have a diverse network of CROs and service providers in one central location who generate an estimated $1 billion in revenue every year and employ more than 9,000 people. We expect BioResearch Central will facilitate continued growth for this important sector."

The KBA commissioned Tufts University to conduct a study quantifying the region's CRO and related services assets in the Kansas City area and in competing markets nationwide. The study found that the Kansas City region's more than 90 CROs and related service providers possess tremendous breadth and depth of expertise – one of the most experienced CRO networks across the country. These CROs are equipped to support both established companies and startups in the pharmaceutical and medical device industries. The members of BioResearch Central are experienced in the full range of bioresearch services, including discovery, formulation, toxicology, bioanalytics, clinical trials, regulatory and commercial support.  

In recent years, the 16 largest global pharmaceutical firms have all enlisted BioResearch Central companies for contract research services. In addition, BioResearch Central companies have contributed to the successful development of more than 60 pharmaceutical products currently being used to treat patients with a variety of conditions.

"The Greater Kansas City region is a proven destination for pharmaceutical research looking to advance their products through the development process," said Terry Osborn, PhD, MBA CEO of KCAS Bioanalytical Laboratories, a Shawnee firm that provides services to drug, biologics and medical device companies. "CROs have contributed to the success of an array of innovative health care products, and the establishment of BioResearch Central will undoubtedly support more innovation, job creation and economic growth in Kansas City's health care community."

About the KBA

The Kansas Bioscience Authority was created by the Kansas Economic Growth Act of 2004 to expand the state's research capacity and bioscience clusters; support the growth of bioscience startups; and stimulate bioscience business expansion and attraction. To learn more, visit www.kansasbioauthority.org.

About BioResearch Central

BioResearch Central is a collaboration of more than 90 contract research organizations and related service providers employing 9,000 people in the Kansas City region. It is supported with efforts from the Kansas Bioscience Authority, Kansas City Area Life Sciences Institute, Kansas City Area Development Council, Kansas BIO, MOBIO, Missouri Technology Corp., Civic Council of Greater Kansas City, local economic development organizations, and the contract research organizations.


'/>"/>
SOURCE BioResearch Central
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
2. The Medical Letter Launches More@MedLetter
3. The official blog of The Medical Letter
4. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
5. Glooko Launches the Glooko™ IR Adapter to Give ACCU-CHEK® Blood Glucose Meter Customers Access to the Glooko Logbook Solution
6. Mylan Launches Generic Version of Lipitor®
7. Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Launches Generic Version of Viramune® Tablets
10. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
11. Mylan Launches Generic Version of Plavix® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):